Liberum Capital downgraded shares of AstraZeneca plc (LON:AZN) from a buy rating to a hold rating in a research note released on Thursday, Marketbeat Ratings reports. The brokerage currently has GBX 5,000 ($64.57) target price on the biopharmaceutical company’s stock, up from their prior target price of GBX 4,800 ($61.99).

AZN has been the topic of a number of other research reports. HSBC Holdings plc restated a reduce rating and set a GBX 4,100 ($52.95) price target on shares of AstraZeneca plc in a report on Monday, September 11th. UBS AG set a GBX 5,150 ($66.51) price target on shares of AstraZeneca plc and gave the company a neutral rating in a report on Tuesday, June 27th. BNP Paribas set a GBX 5,300 ($68.45) price target on shares of AstraZeneca plc and gave the company a neutral rating in a report on Monday, September 11th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($50.37) price target on shares of AstraZeneca plc and gave the company a sell rating in a report on Saturday, May 20th. Finally, Barclays PLC restated an overweight rating and set a GBX 5,500 ($71.03) price target on shares of AstraZeneca plc in a report on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, ten have given a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of GBX 5,022.91 ($64.87).

Shares of AstraZeneca plc (AZN) opened at 4719.50 on Thursday. The company’s 50-day moving average is GBX 4,556.15 and its 200-day moving average is GBX 4,880.61. The stock’s market capitalization is GBX 59.75 billion. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/18/liberum-capital-downgrades-astrazeneca-plc-azn-to-hold.html.

The firm also recently disclosed a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were issued a dividend of GBX 68.90 ($0.89) per share. This represents a dividend yield of 1.35%. The ex-dividend date of this dividend was Thursday, August 10th.

In other AstraZeneca plc news, insider Nazneen Rahman acquired 39 shares of AstraZeneca plc stock in a transaction dated Thursday, July 27th. The stock was bought at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.